Disease · MONDO_0005279
Comparisons in its trials49
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 49
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Apixaban vs Enoxaparin/Warfarin: serious adverse events | 417 of 2,676 | 410 of 2,689 | 5,365 | NCT00643201 | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA: serious adverse events | 504 of 2,412 | 495 of 2,405 | 4,817 | NCT00439777 | Trial comparisons |
| Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA: serious adverse events | 222 of 1,718 | 252 of 1,711 | 3,429 | NCT00440193 | Trial comparisons |
| Apixaban vs Dalteparin: Recurrent Venous Thromboembolism | 32 of 576 | 46 of 579 | 1,155 | NCT03045406 | Trial comparisons |
| Apixaban vs Dalteparin: deaths from any cause | 135 of 576 | 153 of 579 | 1,155 | NCT03045406 | Trial comparisons |
| Apixaban vs Dalteparin: serious adverse events | 255 of 576 | 276 of 579 | 1,155 | NCT03045406 | Trial comparisons |
| Rivaroxaban vs Placebo: Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35 | 4 of 219 | 5 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35 | 6 of 219 | 13 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: Number of Participants With Serious Adverse Events Through Day 35 | 2 of 219 | 7 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: deaths from any cause | 0 of 219 | 0 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: serious adverse events | 2 of 219 | 7 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale Through Day 28 | 46 of 222 | 44 of 222 | 444 | NCT04504032 | Trial comparisons |
| Arm A (Apixaban) vs Arm B (Dalteparin): deaths from any cause | 35 of 148 | 25 of 143 | 291 | NCT02585713 | Trial comparisons |
| Arm A (Apixaban) vs Arm B (Dalteparin): serious adverse events | 62 of 148 | 51 of 143 | 291 | NCT02585713 | Trial comparisons |
| Recombinant Nonimmunogenic Staphylokinase vs Alteplase: Death From All Causes | 6 of 145 | 4 of 146 | 291 | NCT04688320 | Trial comparisons |
| Recombinant Nonimmunogenic Staphylokinase vs Alteplase: Death From PE | 4 of 145 | 2 of 146 | 291 | NCT04688320 | Trial comparisons |
| Recombinant Nonimmunogenic Staphylokinase vs Alteplase: deaths from any cause | 6 of 145 | 4 of 146 | 291 | NCT04688320 | Trial comparisons |
| Recombinant Nonimmunogenic Staphylokinase vs Alteplase: Death From All Causes | 3 of 145 | 4 of 146 | 291 | NCT04688320 | Trial comparisons |
| Recombinant Nonimmunogenic Staphylokinase vs Alteplase: serious adverse events | 9 of 145 | 17 of 146 | 291 | NCT04688320 | Trial comparisons |
| Full Dose LMWH Anticoagulation Therapy vs Prophylactic/Intermediate Dose LMWH or UFH Therapy: Re-hospitalization | 1 of 129 | 3 of 124 | 253 | NCT04401293 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005279/comparisons